24 July 2026 - On 22 July 2026, the FDA approved zidesamtinib (Jideytro, Nuvalent) for adults with locally advanced or metastatic ROS1-positive non-small-cell lung cancer who received at least one prior ROS1 tyrosine kinase inhibitor.

Efficacy was evaluated in ARROS-1, a multi-centre, single-arm, open-label, multi-cohort trial in patients with previously treated locally advanced or metastatic ROS1 positive non-small-cell lung cancer.

Read FDA News